Anbio Biotechnology (NNNN) vs Utah Medical Products (UTMD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Utah Medical Products (UTMD) has outperformed Anbio Biotechnology (NNNN) over the past year, gaining 18.4% versus a loss of 84.3%. Utah Medical Products is the larger company by market cap ($236.6 million vs $204.5 million), about 1.2 times the size. On valuation, Utah Medical Products trades at a lower trailing P/E (22.7x vs 31.1x for Anbio Biotechnology).
Utah Medical Products pays a dividend yielding 1.66%, while Anbio Biotechnology does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NNNN | UTMD |
|---|---|---|
| Share price | $4.66 | $74.54 |
| Market cap | $204.53M | $236.58M |
| 1-day change | +0.87% | +0.90% |
| YTD return | -84.50% | +33.20% |
| 1-year return | -84.25% | +18.45% |
| 5-year return | — | -17.20% |
| P/E ratio (TTM) | 31.07 | 22.73 |
| EPS (TTM) | $0.15 | $3.28 |
| Dividend yield | 0.00% | 1.66% |
| Annual dividend | $0.00 | $1.24 |
| 52-week high | $44.73 | $76.89 |
| 52-week low | $4.20 | $53.66 |
| Distance from 52-week high | -89.58% | -3.06% |
| Average volume | 148.28K | 34.95K |
| Shares outstanding | 43.89M | 3.17M |
| Employees | 27 | 140 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- UTMD has outperformed NNNN by 102.7 percentage points over the past year.
- Anbio Biotechnology trades at a higher earnings multiple (31.1x vs 22.7x trailing P/E).
- Utah Medical Products offers a meaningfully higher dividend yield (1.66% vs 0.00%).
About Anbio Biotechnology
NNNN stock →Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, and internationally. The company offers lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification, SHA dry chemistry, chemiluminescence immunoassay, and real-time polymerase chain reaction solutions; and SARS-CoV-2 and SARS-CoV-2/Flu A/Flu B antigen rapid test kits.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 27 employees
About Utah Medical Products
UTMD stock →Utah Medical Products, Inc. offers medical devices for the healthcare industry in the United States, Europe, and internationally.
Health Care · Medical/Dental Instruments · 140 employees
NNNN vs UTMD FAQ
Which is bigger, Anbio Biotechnology or Utah Medical Products?
Utah Medical Products (UTMD) is larger, with a market capitalization of $236.58M compared with $204.53M for Anbio Biotechnology (NNNN).
Which stock has performed better over the past year, NNNN or UTMD?
UTMD returned +18.45% over the past 12 months, compared with -84.25% for NNNN (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, NNNN or UTMD?
UTMD has the lower trailing P/E at 22.7, versus 31.1 for NNNN. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, Anbio Biotechnology or Utah Medical Products?
Utah Medical Products pays a dividend yielding 1.66%, while Anbio Biotechnology does not currently pay a regular dividend.
Are Anbio Biotechnology and Utah Medical Products in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: In Vitro & In Vivo Diagnostic Substances for Anbio Biotechnology and Medical/Dental Instruments for Utah Medical Products.